CV-08 (Cellivery)

N/A

Report date: 2025/06/11 10:29:54

Base Information

Drug NameCV-08 (Cellivery)
Drug Alias NameCP-deltaSOCS3improved cell-permeable (iCP)-SOCS3 (Cellivery)CV-08-02CV-08-01
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionLeptin receptor antagonists
TargetsLeptin receptor
Therapy Area/IndicationsObesityCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCellivery Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesCellivery Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsObesityCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A